Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Optimizing Antimicrobial Stewardship (AMS) Interventions and Outcomes in Clinical Outcomes, Optimal Use and Resource UtilizatioRelease Date:Research Inflammation & Immunology China Optimizing Disease Management to Improve Alopecia Areata Quality of CareRelease Date:Quality Improvement Inflammation & Immunology China Research on Exploring Disease Assessment and Prioritizing Systematic Treatment for VitiligoRelease Date:Research Inflammation & Immunology China Quality Improvement in Molecular Testing Pathways for Metastatic Colorectal Cancer (mCRC)Release Date:Partner: American Society for Clinical Pathology (ASCP)Quality Improvement Oncology USA Personalized monitoring&treatment for HR+, HER2- mBC patients treated w CDK4/6i: incorporating Patient complexity risk factorsRelease Date:Quality Improvement, Research Oncology Italy Providing Appropriate Medical Care for IBD PatientsRelease Date:Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD)Quality Improvement Inflammation & Immunology Japan Administration of brentuximab vedotin alone or in combination with other approved agents in pre and/or peri CAR-TRelease Date:Research Oncology USA Fostering Educational Initiatives for ALK+ Metastatic Non-Small Cell Lung Cancer(mNSCLC) Tyrosine Kinase Inhibitors(TKI) TherapyRelease Date:Education Oncology Canada 2026 Inflammatory Bowel Disease (IBD) Fellowship- United StatesRelease Date:Fellowship Inflammation & Immunology USA Title Grant Type Focus Area Country Application Due Date Optimization of Health IT to support RSV ImmunizationsRelease Date:Quality Improvement Vaccines USA New Mechanisms and Emerging Treatment Options in Metastatic Castration Resistant Prostate Cancer (mCRPC)Release Date:Education Oncology All Diagnosis and Risk Factors for Invasive Mold InfectionsRelease Date:Education Hospital All Early Diagnosis Improvement of Chlamydia InfectionsRelease Date:Education Hospital All Best Practices for Drug-Drug Interactions (DDIs) Management for Oral COVID-19 AntiviralsRelease Date:Education Vaccines USA HER2+ Metastatic Breast Cancer (MBC) Care in Second-Line Treatment and BeyondRelease Date:Education Oncology USA Addressing Healthcare Disparities in the Outpatient Diagnosis and Management of COVID-19Release Date:Education Vaccines USA Treating Older Patients with HR+/HER2- Metastatic Breast Cancer (mBC): Best Practices for Their Assessment and CareRelease Date:Education Oncology USA Treating the Whole Patient: Considerations for Patients with HR+/HER2- Metastatic Breast Cancer (mBC) and Existing ComorbiditiesRelease Date:Education Oncology USA Optimizing Testing and Treatment in Metastatic Colorectal Cancer (mCRC)Release Date:Education Oncology USA Increase Awareness & Understanding of Emerging Hemophilia Treatment OptionsRelease Date:Education Rare Disease USA Closing the Gaps within Intestinal UltrasoundRelease Date:Partner: International Bowel Ultrasound GroupResearch Inflammation & Immunology All